Granzyme B directed imaging and therapy

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, or a stereoisomer or tautomer thereof,
• wherein:
• m is 1;
• n is 1,2, or 3;
• R1 is NR10R12, and at least one of R10 and R12 is —C(O)C6-10 aryl, —C(O)C6-10 cycloalkyl or —C(O)HET;
• R2 is selected from the group consisting of:
• hydrogen, C1-6 alkyl, C1-6 alkoxy, C3-6 cycloalkyl, C6-10 aryl, HET and NR10R12, wherein each C1-6 alkyl, C1-6 alkoxy, C3-6 cycloalkyl, are optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo and hydroxy, and C6-10 aryl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of oxo, halo, hydroxy, C1-4 alkyl and C1-4 haloalkyl;
• each R3 and R7 is independently selected from the group consisting of hydrogen, C1-4 alkyl and C1-4 haloalkyl;
• X is CH2;
• each R5, R6, R8′ and R8 is independently selected from the group consisting of hydrogen, halo, COOH, hydroxy, OC1-4 alkyl, C1-4 alkyl and C1-4 haloalkyl;
• R9 is 1,2,4-triazolyl, 1,2,3-triazolyl, or tetrazolyl;
• R10 is selected from the group consisting of hydrogen, C1-4 alkyl, —C(O)C6-10 aryl, —C(O)C6-10 cycloalkyl, —C(O)HET and —C(O)C1-4 alkyl;
• wherein the C1-4 alkyl is optionally substituted with 1, 2, or 3 halo groups;
• wherein the —C(O)C1-4 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, oxo, —N(R11)2, HET, —O—C1-4 alkyl and C6-10 aryl;
• wherein the —O—C1-4 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, oxo, —N(R11)2 and C6-10 aryl;
• wherein the C6-10 aryl is optionally substituted with 1, 2, or 3 halo groups and wherein the —C(O)C6-10 aryl, and —C(O)C6-10 cycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, —O—C1-4 alkyl, —O—C1-4 haloalkyl and halo groups;
• each HET is independently a mono- or bicyclic 5-10-membered heteroaryl or a mono- or bicyclic 5-10 membered heterocycloalkyl group, wherein each HET comprises 1, 2, 3, or 4 heteroatoms selected from O, S and N and is optionally substituted with 1 or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, —O—C1-4 alkyl, —O—C1-4 haloalkyl, halo, hydroxy and oxo groups;
• R11 is selected from hydrogen, C1-4 alkyl and C1-4 haloalkyl;
• and
• R12 is selected from the group consisting of C1-4 alkyl, —C(O)C6-10 aryl, —C(O)C6-10 cycloalkyl, —C(O)HET and —C(O)C1-4 alkyl;
• wherein the C1-4 alkyl is substituted with 1, 2, or 3 halo groups;
• wherein the —C(O)C1-4 alkyl is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, —O—C1-4 alkyl and C6-10 aryl;
• wherein the —O—C1-4 alkyl is substituted with 1, 2, or 3 halo;
• wherein the C6-10 aryl is substituted with 1, 2, or 3 halo groups and wherein the —C(O)C6-10 aryl, and —C(O)C6-10 cycloalkyl is substituted with 1, 2, or 3 halo groups.